The features of the course of HBV infection during antiviral therapy


DOI: https://dx.doi.org/10.18565/epidem.2022.12.1.60-3

Omarova Kh.G., Makashova V.V., Ponezheva Zh.B.

Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia
Objective. To determine the features of the course of chronic hepatitis B in patients receiving and not receiving antiviral therapy (AVT).
Subjects and methods. Seventy HBsAg-positive patients were followed up who had a disease duration from 1 to 15 years; of them there were 24 (34.3%) patients who received AVT with nucleoside analogues (NAs) and 46 (65.7%) who did not receive treatment.
Results. During the first visit, the duration of HBsAg release was less than 5 years in 57% of the patients. The number of patients with a duration of HBsAg release for more than 20 years coincided with that of patients (11%) with severe fibrosis (F3-F4), which was evidenced by fibroelastometry using a FibroScan. HBeAg-negative HBV infection was identified in 86% of the patients; and the initial stage of fibrosis was detected in 83%. AVT was initiated, regardless of the stage of fibrosis, more often in patients aged 41–60 years (in 41.7% of cases) with a viral load of 5 logs.
Conclusion. Less than half of the patients who started taking NAs remained adherent to therapy. At the same time, the stage of liver fibrosis decreased in patients receiving AVT, which may suggest that NAs have an anti-fibrotic effect.
Keywords: hepatic fibrosis, chronic hepatitis B, antiviral therapy
Read entire article

Literature

1. WHO. Global Hepatitis Report 2017. Geneva, Switzerland. World Health Organization, 2017. https://apps.who.int/iris/bitstream/handle/10665/ 255016/9789241565455-eng.pdf


2. Fattovich G., Bertoletti F., Donato F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J. Hepatol. 2008; 48, 335–52. doi: 10.1016/j.jhep.2007.11.011


3. MacLachlan J.H.,Cowie B.C. Hepatitis B virus epidemiology. Cold Spring Harb. Perspect. Med. 2015; 5(5): a021410. doi: 10.1101/cshperspect. a021410


4. Ющук Н.Д., Климова Е.А., Знойко О.О., Кареткина Г.Н., Максимов С.Л., Маев И.В. Вирусные гепатиты. Клиника, диагностика, лечение. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2015. 302 с.

Yushchuk N.D., Klimova E.A., Znoуko O.O., Karetkina G.N.. Maksimov S.L., Mayev I.V. [Viral hepatitis. Clinic, diagnostics, treatment]. 2nd edition, revised and supplemented. Moscow: GEOTAR-Media, 2015. 302 р. (In Russ.).


5. Абдурахманов Д.Т. Хронический гепатит В и D. М.: ГЭОТАР-Медиа, 2010. 286 с.

Abdurakhmanov D.T. [Chronic hepatitis B and D]. Moscow: GEOTAR-Media, 2010. 286 р. (In Russ.).


6. Weinbaum C., Williams I., Mast E., Wang S.A., Finelli L., Wasley A. et al. Recommendations for identication and public health manage-ment of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 2008; 57: 1–20.


7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of chronic hepatitis В virus infection. J. Hepatol. 2017; 67(2): 370–98. doi: 10.1016/j.jhep.2017.03.021


8. Chou R., Dana T., Bougatsos S., Blazina I., Khangura J., Zakher B. Screening for hepatitis B virus infection in adolescents and adults: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann. Intern. Med. 2014; 161: 31–45. doi: 10.7326/M13-2837


9. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., Lok A.S.F. Management of hepatitis B: Summary of a clinical research workshop. Hepatology 2007; 45(4): 1056–75. DOI: 10.1002/hep.21627


10. Sweetman S., ed. Martindale: the complete drug reference (online version), 37th edition, 2011. http://www.pharmpress.com/product/MC_MART/ martindale-the-complete-drug-reference


11. Terrault N.A., Lok A.S., McMahon B.J., Chang K.-M., Hwang J/P., Jonas M.M. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67(4): 1560–99. doi: 10.1002/hep.29800


12. Schiff E.R., Lee S.S., Chao Y.C., You-Chen Chao, Seung Kew Yoon et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin. Gastroenterol. Hepatol. 2011; 9(3): 274–6. DOI: 10.1016/j.cgh.2010.11.040


13. Yeo Y.H., Ho H.J., Yang H.I., Tseng T.C., Hosaka T., Trinh H.N. et al. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology 2019; 156(3): 635–646.e9. doi: 10.1053/j.gastro.2018. 10.027


14. Chu C.M., Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45(5): 1187–92. doi: 10.1002/hep.21612


15. Okada M., Enomoto M., Kawada N.,Nguyen M.N. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis . Expert Rev. Gastroenterol. Hepatol. 2017; 11: 1095–104. DOI: 10.1080/17474124. 2017. 1361822


16. Marcellin P., Gane E., Buti M., Afdhal N., Sievert W., Jacobson I.M. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381(9865): 468–75. DOI: 10.1016/S0140-6736(12)61425-1


17. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. European Association for the Study of the Liver. J Hepatol 2017; 67 (2): 370–398. DOI: 10.1016/j.jhep.2017.03.021


About the Autors

Khadizhat G. Omarova, Cand. Med. Sci., Researcher, Clinical Department of Infectious Diseases, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; omarova71@inbox;ru; http://orcid.org/0000-0002-9682-2230
Professor Vera V. Makashova, MD, Leading Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; veramakashova@yandex.ru; https://orcid.org/0000-0002-0982-3527
Zhanna B. Ponezheva, MD, Head, Clinical Department of Infectious Diseases, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; doktorim@mail.ru; https://orcid.org/0000-0002-6539-4878


Similar Articles

Back to Content

Бионика Медиа